Glenmark Pharmaceuticals receives USFDA approval for Rufinamide Tablets USP

21 May 2015 Evaluate

Glenmark Pharmaceuticals Inc., USA, has been granted tentative approval last week by the United States Food & Drug Administration (USFDA) for its Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel Tablets of Eisai, Inc. Under the terms of a settlement agreement between Glenmark and Eisai, Glenmark will be permitted to market this product in the United States on May 30, 2022 or potentially earlier under certain circumstances.

The Banzel market achieved annual sales of approximately $121.8 million, according to IMS Health sales data for the 12 month period ending March 2015.

Glenmark’s current portfolio consists of 96 products authorized for distribution in the US marketplace and 68 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

1958.50 5.60 (0.29%)
11-Dec-2025 12:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.25
Dr. Reddys Lab 1274.00
Cipla 1508.40
Zydus Lifesciences 925.30
Lupin 2078.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×